Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis.

Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L, Dalekos GN, Rodes J, Vergani D.

Hepatology. 2007 Jun;45(6):1583; author reply 1583-4. No abstract available.

PMID:
17538935
2.

The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.

Luettig B, Boeker KH, Schoessler W, Will H, Loges S, Schmidt E, Worman HJ, Gershwin ME, Manns MP.

J Hepatol. 1998 May;28(5):824-8.

PMID:
9625318
3.

[Investigating the relationship between anti-gp210 antibody and clinical basic profile of primary billiary cirrhosis].

Yang J, Yang JH, You LY, Xu ZY, Yang LH.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jun;17(6):468-9. Chinese. No abstract available.

PMID:
19567032
4.

Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies.

Wesierska-Gadek J, Klima A, Komina O, Ranftler C, Invernizzi P, Penner E.

Ann N Y Acad Sci. 2007 Aug;1109:519-30.

PMID:
17785341
5.

Persistence of gp210 and multiple nuclear dots antibodies does not correlate with recurrence of primary biliary cirrhosis 6 years after liver transplantation.

Dubel L, Farges O, Courvalin JC, Sebagh M, Johanet C.

J Hepatol. 1998 Jan;28(1):169-70. No abstract available.

PMID:
9537858
6.

Antinuclear antibodies in primary biliary cirrhosis.

Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J.

Semin Liver Dis. 2005 Aug;25(3):298-310. Review.

PMID:
16143945
7.

Autoantibodies in primary biliary cirrhosis: antinuclear envelope autoantibodies.

Chantran Y, Ballot E, Johanet C.

Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):256-8. doi: 10.1016/j.clinre.2013.10.008. Epub 2013 Nov 20. Review. No abstract available.

PMID:
24268998
8.

Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: a case-based review.

Valour F, Durupt S, Khenifer S, Durieu I.

BMJ Case Rep. 2013 Jun 26;2013. pii: bcr2013009803. doi: 10.1136/bcr-2013-009803.

9.

Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.

Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, Daikoku M, Yano K, Matsumoto T, Migita K, Yatsuhashi H, Ito M, Masaki N, Adachi H, Watanabe Y, Nakamura Y, Saoshiro T, Sodeyama T, Koga M, Shimoda S, Ishibashi H.

J Hepatol. 2005 Mar;42(3):386-92.

PMID:
15710222
10.

Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis.

Nickowitz RE, Wozniak RW, Schaffner F, Worman HJ.

Gastroenterology. 1994 Jan;106(1):193-9.

PMID:
8276182
11.

Antinuclear antibodies specific for primary biliary cirrhosis.

Worman HJ, Courvalin JC.

Autoimmun Rev. 2003 Jun;2(4):211-7. Review.

PMID:
12848948
12.

Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.

Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, Linares A, Fuentes D, Bianchi FB.

Am J Gastroenterol. 2003 Feb;98(2):431-7.

PMID:
12591064
13.

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.

Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, Saoshiro T, Harada H, Sodeyama T, Hayashi S, Masumoto A, Sando T, Yamamoto T, Sakai H, Kobayashi M, Muro T, Koga M, Shums Z, Norman GL, Ishibashi H.

Hepatology. 2007 Jan;45(1):118-27.

PMID:
17187436
14.

[The significance of anti-nuclear envelope (gp210) antibody in primary biliary cirrhosis].

Nakamura M.

Nihon Rinsho Meneki Gakkai Kaishi. 2005 Jun;28(3):117-22. Review. Japanese.

16.

Is prevalence of PBC underestimated in patients with systemic sclerosis?

Norman GL, Bialek A, Encabo S, Butkiewicz B, Wiechowska-Kozlowska A, Brzosko M, Shums Z, Milkiewicz P.

Dig Liver Dis. 2009 Oct;41(10):762-4. doi: 10.1016/j.dld.2009.01.014. Epub 2009 Apr 7.

PMID:
19357001
17.

Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients.

Sfakianaki O, Koulentaki M, Tzardi M, Tsangaridou E, Theodoropoulos PA, Castanas E, Kouroumalis EA.

World J Gastroenterol. 2010 Oct 21;16(39):4938-43.

18.

Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis.

Bauer A, Habior A.

J Clin Lab Anal. 2007;21(4):227-31.

PMID:
17621358
19.

Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.

Hu SL, Zhao FR, Hu Q, Chen WX.

PLoS One. 2014 Jul 10;9(7):e101916. doi: 10.1371/journal.pone.0101916. eCollection 2014.

20.

[Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis].

Romero Gómez M, Wichmann I, Otero Fernández MA, Suárez García E, Grande L, Núñez J, Nevado Santos M, Castro Fernández M.

Gastroenterol Hepatol. 1999 Jan;22(1):11-3. Review. Spanish.

PMID:
10089705

Supplemental Content

Support Center